Sequential Chemo-Immunotherapy as a Novel Bridging Strategy for Non-Complete Responders after Neoadjuvant Chemoradiotherapy in Esophageal Cancer: First Prospective Phase 2 Trial Challenging Immediate Surgery Paradigm
Purpose/Objective(s): Non-clinical complete responders (non-CCR) after
neoadjuvant chemoradiotherapy (NCRT) for locally advanced esophageal
squamous cell carcinoma (LA-ESCC) face high recurrence risks with
immediate surgery. This first study evaluates the efficacy and safety of sequential chemo-immunotherapy (SCI) as a bridge to surgery in this population.
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2025]版：
大类|1 区医学
小类|2 区肿瘤学2 区核医学
最新[2025]版：
大类|1 区医学
小类|2 区肿瘤学2 区核医学
JCR分区：
出版当年[2024]版：
Q1ONCOLOGYQ1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2024]版：
Q1ONCOLOGYQ1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Wang Q.,Peng L.,Wang C.,et al.Sequential Chemo-Immunotherapy as a Novel Bridging Strategy for Non-Complete Responders after Neoadjuvant Chemoradiotherapy in Esophageal Cancer: First Prospective Phase 2 Trial Challenging Immediate Surgery Paradigm[J].INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS.2025,123(1):
APA：
Wang, Q.,Peng, L.,Wang, C.,He, W.,Wu, L....&Han, Y..(2025).Sequential Chemo-Immunotherapy as a Novel Bridging Strategy for Non-Complete Responders after Neoadjuvant Chemoradiotherapy in Esophageal Cancer: First Prospective Phase 2 Trial Challenging Immediate Surgery Paradigm.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS,123,(1)
MLA：
Wang, Q.,et al."Sequential Chemo-Immunotherapy as a Novel Bridging Strategy for Non-Complete Responders after Neoadjuvant Chemoradiotherapy in Esophageal Cancer: First Prospective Phase 2 Trial Challenging Immediate Surgery Paradigm".INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 123..1(2025)
医学